Pfizer stock jumps as PFE taps a Swiss biotech incubator — here’s what Wall Street is watching next
Pfizer shares rose 2.1% to $27.62 Tuesday afternoon after Swiss incubator BaseLaunch announced Pfizer as its newest pharma partner. The move outpaced a flat U.S. healthcare sector. Investors remain focused on Pfizer’s 2026 pipeline and recent obesity-drug data. The FDA granted Priority Review for Pfizer’s hemophilia drug HYMPAVZI, with a decision expected in Q2 2026.
